Researchers are exploring drugs like Ozempic, Mounjaro, and Wegovy to treat or prevent a range of conditions, including ...

GLP-1 RAs show greater cardiovascular benefits in type 2 diabetes patients with BMI ≥25 compared to DPP-4 inhibitors. Kidney protection from GLP-1 RAs remains consistent across all BMI categories. The ...

Discover a study comparing tirzepatide, semaglutide, and liraglutide in MASLD, revealing significant reductions in liver ...

(HealthDay News) — People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems compared with patients treated with glucagon-like peptide-1 ...

An estimated 25% of Medicaid enrollees had restricted availability of SGLT2 inhibitors and 40% had restricted availability of GLP-1 agents. Availability of GLP-1 receptor agonists with managed care ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. GLP-1 receptor agonists reduced mortality vs. DDP-4 ...

SAN DIEGO — Patients with obesity and diabetes are at a substantially reduced risk of having a recurrence of atrial fibrillation (AF) after ablation if they are taking a glucagon-like peptide 1 (GLP-1 ...

May 22 (Reuters) - Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's (NOVOb.CO), opens new tab Ozempic may modestly reduce the risk of obesity-related cancers, especially colorectal ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on ...

Although the use of glucagon-like peptide 1 (GLP-1) receptor agonists and other antidiabetic medications continues to increase among pregnant women with type 2 diabetes, current evidence suggests no ...